Shield Therapeutics (STX LN)

Analysis

Health Care • United Kingdom

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on pharmaceuticals for unmet medical needs. Its primary product, Accrufer/Feraccru (ferric maltol), is an oral therapy for iron deficiency with or without anemia. The company was founded in 2008 and is headquartered in Gateshead, United Kingdom.

Refresh

Exchange Announcement • 30 Sep 2026 13:00

Total Voting Rights

Exchange Announcement • 01 Sep 2026 13:00

Total Voting Rights

Exchange Announcement • 27 Aug 2026 22:00

Shield assumes full control of ACCRUFeR® in the US

Exchange Announcement • 20 Aug 2026 13:00

Interim results for the six months ended 30 Jun 26

Exchange Announcement • 03 Aug 2026 18:02

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00